UA130186C2 - Інгібітор magl - Google Patents

Інгібітор magl

Info

Publication number
UA130186C2
UA130186C2 UAA202301351A UAA202301351A UA130186C2 UA 130186 C2 UA130186 C2 UA 130186C2 UA A202301351 A UAA202301351 A UA A202301351A UA A202301351 A UAA202301351 A UA A202301351A UA 130186 C2 UA130186 C2 UA 130186C2
Authority
UA
Ukraine
Prior art keywords
octane
azaspiro
carboxylate
hexafluoropropane
carbamoyl
Prior art date
Application number
UAA202301351A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джон Дж. М. Вьєнер
Черіл А. Гріс
Деніел Дж. Бузард
Джастін С. Цісар
Олівія Д. Вебер
Емі Аллан
Ніколас Раффаель
Джинн В. Муді
Майкл Б. Шагафі
Original Assignee
Х. Луннбек А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Луннбек А/С filed Critical Х. Луннбек А/С
Publication of UA130186C2 publication Critical patent/UA130186C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA202301351A 2020-11-13 2021-11-12 Інгібітор magl UA130186C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113662P 2020-11-13 2020-11-13
PCT/EP2021/081522 WO2022101412A1 (en) 2020-11-13 2021-11-12 A magl inhibitor

Publications (1)

Publication Number Publication Date
UA130186C2 true UA130186C2 (uk) 2025-12-10

Family

ID=78709459

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202301351A UA130186C2 (uk) 2020-11-13 2021-11-12 Інгібітор magl

Country Status (33)

Country Link
US (2) US11434222B2 (https=)
EP (2) EP4244208B1 (https=)
JP (1) JP2023549051A (https=)
KR (1) KR20230107225A (https=)
CN (2) CN116547274B (https=)
AR (1) AR124057A1 (https=)
AU (1) AU2021379081A1 (https=)
CA (1) CA3196119A1 (https=)
CL (1) CL2023001339A1 (https=)
CO (1) CO2023004649A2 (https=)
CR (1) CR20230203A (https=)
DK (1) DK4244208T3 (https=)
DO (1) DOP2023000086A (https=)
ES (1) ES3025484T3 (https=)
FI (1) FI4244208T3 (https=)
GE (2) GEP20257794B (https=)
HR (1) HRP20250644T1 (https=)
HU (1) HUE071543T2 (https=)
IL (1) IL301818B1 (https=)
JO (1) JOP20230091A1 (https=)
LT (1) LT4244208T (https=)
MA (1) MA62148B1 (https=)
MX (1) MX2023005576A (https=)
PL (1) PL4244208T3 (https=)
PT (1) PT4244208T (https=)
RS (1) RS66839B1 (https=)
SA (1) SA523440403B1 (https=)
SI (1) SI4244208T1 (https=)
TW (1) TWI904281B (https=)
UA (1) UA130186C2 (https=)
UY (1) UY39516A (https=)
WO (1) WO2022101412A1 (https=)
ZA (1) ZA202304134B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) * 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2429991A (en) * 2005-09-07 2007-03-14 Alan Barrows Water powered impulsive unit
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100113465A1 (en) * 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
WO2012047703A2 (en) * 2010-10-04 2012-04-12 Schering Corporation Cyclopropyl-spiro-piperidines useful as sodium channel blockers
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
JP6404717B2 (ja) * 2012-03-02 2018-10-17 ジェネンテック, インコーポレイテッド アミドスピロ環状アミド及びスルホンアミド誘導体
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
JP2018513119A (ja) 2015-03-18 2018-05-24 アビデ セラピューティクス,インク. ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017083867A1 (en) * 2015-11-12 2017-05-18 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN110198944A (zh) * 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
CN111032034B (zh) * 2017-08-29 2023-05-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
KR20250005229A (ko) * 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Also Published As

Publication number Publication date
IL301818A (en) 2023-06-01
US20220153721A1 (en) 2022-05-19
SI4244208T1 (sl) 2025-07-31
EP4244208A1 (en) 2023-09-20
IL301818B1 (en) 2026-02-01
CA3196119A1 (en) 2022-05-19
ES3025484T3 (en) 2025-06-09
PT4244208T (pt) 2025-05-22
GEP20257794B (en) 2025-09-10
TWI904281B (zh) 2025-11-11
CR20230203A (es) 2023-06-14
MX2023005576A (es) 2023-05-29
HUE071543T2 (hu) 2025-09-28
EP4244208B1 (en) 2025-04-02
DK4244208T3 (da) 2025-05-26
PL4244208T3 (pl) 2025-06-30
TW202229255A (zh) 2022-08-01
WO2022101412A1 (en) 2022-05-19
KR20230107225A (ko) 2023-07-14
EP4574150A2 (en) 2025-06-25
AR124057A1 (es) 2023-02-08
DOP2023000086A (es) 2023-06-30
FI4244208T3 (fi) 2025-06-10
RS66839B1 (sr) 2025-06-30
AU2021379081A1 (en) 2023-05-18
ZA202304134B (en) 2024-08-28
JP2023549051A (ja) 2023-11-22
SA523440403B1 (ar) 2024-10-10
JOP20230091A1 (ar) 2023-05-01
UY39516A (es) 2022-05-31
CN116547274A (zh) 2023-08-04
EP4574150A3 (en) 2025-08-20
LT4244208T (lt) 2025-06-10
US20240018120A1 (en) 2024-01-18
US11434222B2 (en) 2022-09-06
MA62148B1 (fr) 2025-05-30
CL2023001339A1 (es) 2023-10-20
HRP20250644T1 (hr) 2025-07-18
CN116547274B (zh) 2026-02-13
CN121824488A (zh) 2026-04-10
GEAP202516246A (en) 2025-04-10
CO2023004649A2 (es) 2023-05-08

Similar Documents

Publication Publication Date Title
UA130186C2 (uk) Інгібітор magl
JP2024501641A (ja) 置換大環状化合物及び関連する治療方法
CN120699028A (zh) Nek7激酶的抑制剂
JP7201688B2 (ja) 置換テトラヒドロピランジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
JP2013507364A (ja) 新規なtrpa1アンタゴニスト
RU2717665C2 (ru) Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата
CA3163933A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EA030938B1 (ru) Производные карбоксамида
CA3186041A1 (en) Inhibitors of nek7 kinase
EP4317164A1 (en) Spiro-containing derivative, and preparation method therefor and use thereof
RU2644558C2 (ru) Гетероарильные соединения и способы их применения
CN104011048B (zh) 作为磷酸二酯酶抑制剂的[1,2,4]三唑并吡啶类化合物及其应用
KR20250164854A (ko) 치환된 인다졸 프로피온산 유도체 화합물 및 ampk 활성제로서의 이의 용도
WO2024196786A1 (en) Urea derivatives for inhibiting nlrp3 and uses thereof
JP2013231000A (ja) 3−アミノメチルピラゾール誘導体
HK40100721A (en) A magl inhibitor
HK40100721B (en) A magl inhibitor
EA048915B1 (ru) Ингибитор magl
TWI893772B (zh) 作為tyk2抑制劑的雜環化合物及合成與應用
WO2025221732A1 (en) Nmda receptor-modulating compounds and methods of use thereof
JP2026509195A (ja) 代謝型グルタミン酸受容体2のネガティブアロステリックモジュレーター
JP2025521070A (ja) Tyk2阻害剤として機能する置換ピリダジン-3-カルボキサミド化合物